Glaucoma market to hit $2.5b in seven major markets by 2033

A report predicts the launch of six late-stage pipeline drugs during this period.

The glaucoma market across the seven major markets (7MM) is projected to reach $2.5b by 2033 at a compound annual growth rate of 2.1%, according to GlobalData.

The sector’s expansion is attributed to an ageing population driving increased prevalence of the condition and the introduction of pipeline products.

The report predicts the launch of six late-stage pipeline drugs during this period, including prostaglandin analogues, intracameral implants, and therapies with novel mechanisms of action.

“However, the crowded and highly genericised nature of the glaucoma market represents significant competition for new therapies,” said Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData.

Meanwhile, key opinion leaders (KOLs) and prescribers identified poor patient compliance as a primary unmet need.

The market also demands therapies with enhanced intraocular pressure (IOP)-lowering capabilities, neuroprotective properties, and advancements in disease diagnosis and monitoring.

“KOLs have expressed enthusiasm about this shift, emphasising the growing need to optimise the delivery of existing treatments rather than focusing solely on creating novel therapies beyond IOP lowering,” Mohammad added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan